EcolabECL
ECL logo
Fair Value
US$323.71
Share price30 Jul
US$283.712.4% undervalued intrinsic discount
Loading
1Y7.82%
7D6.30%

Margin Expansion And Digital Solutions Will Drive Outperformance Over The Next Few Years

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
06 Aug 24
Updated
30 Jul 26
Views
564
Not Invested

Last Update 30 Jul 26

Fair value Increased 2.07%

ECL: High Tech And AI Data Center Demand Will Drive Future Upside

Ecolab’s updated analyst price target edges higher to about $324 from about $317. This reflects analyst views that rising organic sales, stronger contributions from high tech and bio processing, and ongoing pricing and digital initiatives support slightly higher expected growth and margin assumptions, despite a modestly higher discount rate and a lower future P/E multiple.

Analyst Commentary

Ecolab is attracting a generally constructive tone from Wall Street, with several bullish analysts lifting price targets and a few taking a more measured stance on current valuation and execution risk. The focus is squarely on how the company converts its sales opportunities and cost profile into sustained earnings power.

Bullish Takeaways

  • Bullish analysts point to Q2 organic sales growth of 5% as support for a stronger growth profile, which in their view can help justify higher valuation multiples over time if execution remains consistent.
  • Multiple firms highlight Ecolab's growing exposure to high tech and bio processing as important growth engines. These areas are seen as supporting volume growth and potentially higher margin contribution compared with the legacy mix.
  • Several reports emphasize Ecolab's pricing power and ability to convert temporary surcharges into more structural pricing as raw material pressures ease. This is cited as a key driver for earnings and cash flow durability.
  • Digital solutions across areas such as pest and broader service offerings are viewed as supporting better customer retention and higher value per customer, which bullish analysts see as supportive for both growth and margins.

Bearish Takeaways

  • Some cautious analysts flag that the stock already trades at rich P/E levels relative to historical norms, which can limit upside if growth or margin progress tracks closer to current expectations rather than surprising positively.
  • There is attention on muted underlying volumes in some businesses, even as surcharges and pricing support revenue. This raises questions about how much of the current revenue run rate reflects sustainable demand versus pricing mechanics.
  • Execution risk remains around Ecolab's push into higher growth verticals such as high tech and data centers. If these initiatives scale more slowly than hoped, it could weigh on the growth narrative relative to current analyst optimism.
  • A few firms maintain more neutral stances and point to the need for ongoing cost discipline and consistent delivery on margin expansion targets. Any slip in cost control or pricing resilience could pressure both earnings and valuation.

What’s in the News for Ecolab

  • Oppenheimer upgraded Ecolab to Outperform and highlighted the strength of the core business along with a growing contribution from the Global High Tech segment. The firm pointed to improving operational momentum and a view that current earnings trends support expectations for faster earnings growth. Source: Oppenheimer research coverage.
  • The upgrade from Oppenheimer also raised the question of whether Ecolab’s current valuation already reflects the more positive outlook or if there could be additional upside that is not yet fully priced. Source: Oppenheimer research coverage.
  • From April 1, 2026 to June 30, 2026, Ecolab repurchased 1,200,000 shares, equal to 0.43% of shares, for US$316.13 million. Since the start of the buyback announced on February 26, 2010, the company has repurchased 61,556,512 shares, equal to 22.81% of shares, for a total of US$7.55b.
  • Ecolab was removed from several Russell growth-oriented indexes, including the Russell 3000 Growth Benchmark, Russell 1000 Growth Benchmark, Russell 3000E Growth Benchmark, Russell 1000 Growth Defensive Index, and Russell Top 200 Growth Benchmark.
  • J.P. Morgan Securities, Wells Fargo Securities, Barclays Capital, Citigroup Global Markets, Goldman Sachs, SMBC Nikko Securities America, BofA Securities, and U.S. Bancorp Investments were added as co-lead underwriters for Ecolab’s US$1.20b fixed income offering.

Valuation Changes for Ecolab

  • Fair Value has risen slightly from about $317.14 to about $323.71, reflecting a modest uplift in the valuation model for Ecolab.
  • Discount Rate has edged higher from 7.41% to 7.45%, which implies a slightly more conservative hurdle rate applied to future cash flows.
  • Revenue Growth has moved up from 7.16% to 7.46%, indicating a small adjustment to expected top line expansion for Ecolab in the model.
  • Net Profit Margin has increased from 15.45% to 15.80%, pointing to a modestly higher assumed level of earnings efficiency.
  • Future P/E has been reduced from 34.43x to 33.07x, which means the updated valuation relies on a slightly lower earnings multiple.
0 viewsusers have viewed this narrative update

Key Takeaways

  • Ecolab's One Ecolab initiative focuses on market share gains and value pricing, aiming to improve revenue growth and net margins by delivering exceptional customer value.
  • Strategic pricing adjustments, digital technology investments, and Life Sciences growth position Ecolab for improved operating income margins and long-term earnings potential.
  • Softer demand, international tariffs, and local supplier costs may compress margins, despite strategic investments that could offer long-term growth.

Catalysts

About Ecolab
    Provides water, hygiene, and infection prevention solutions and services in the United States and internationally.
What are the underlying business or industry changes driving this perspective?
  • Ecolab is focusing on expanding its One Ecolab growth initiative, aiming to capitalize on market share gains and increased value pricing. This initiative is expected to drive revenue growth and improve net margins by delivering exceptional value to customers.
  • Investments in digital technologies have led to improved productivity, resulting in a 190-basis-point increase in operating income margin. Continued investment in these technologies is anticipated to enhance earnings and operating margins further.
  • The company has announced a 5% trade surcharge to offset the impact of tariffs, expecting it to bolster organic sales growth and support operating margins by the third quarter. Such strategic pricing adjustments can protect revenue and profitability from global trade fluctuations.
  • Life Sciences is positioned for accelerated long-term growth, with mid-single-digit sales growth and significant share gains in its biopharma business. Investments in innovation and capacity expansion are anticipated to achieve operating income margins close to 30%, positively affecting long-term earnings potential.
  • Ecolab digital experienced a 12% sales growth, primarily driven by subscription revenue, and the company aims to capitalize on this high-margin opportunity by expanding digital offerings. This is expected to significantly impact sales growth and operating income margins as these offerings scale.
Ecolab Earnings and Revenue Growth

Ecolab Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

  • Analysts are assuming Ecolab's revenue will grow by 7.5% annually over the next 3 years.
  • Analysts assume that profit margins will increase from 12.6% today to 15.8% in 3 years time.
  • Analysts expect earnings to reach $3.3 billion (and earnings per share of $11.0) by about July 2029, up from $2.1 billion today. The analysts are largely in agreement about this estimate.
  • In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 33.1x on those 2029 earnings, down from 37.7x today. This future PE is greater than the current PE for the US Chemicals industry at 25.2x.
  • Analysts expect the number of shares outstanding to decline by 1.03% per year for the next 3 years.
  • To value all of this in today's terms, we will use a discount rate of 7.45%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?
  • Softer demand in heavy industrial markets and expectations of continued softness, particularly as customer production rates in some industries have eased, could impact revenue growth.
  • Rapid changes in international trade policies and global tariffs, particularly the 145% tariff on China, are increasing costs related to raw materials, packaging, and equipment, which could affect net margins.
  • While strategic investments in growth engines like Life Sciences and Pest Intelligence may fuel long-term growth, they could have a near-term impact on operating income margins as these initiatives ramp up.
  • The global onshoring trend has increased local supplier costs due to higher demand, which could compress margins if not offset by cost efficiencies and surcharges.
  • Price surcharges like the newly announced 5% trade surcharge in the U.S. could face resistance from customers, potentially impacting sales volumes and complicating the company's pricing strategy.

Valuation

How have all the factors above been brought together to estimate a fair value?

  • The analysts have a consensus price target of $323.71 for Ecolab based on their expectations of its future earnings growth, profit margins and other risk factors.
  • However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $360.0, and the most bearish reporting a price target of just $275.0.
  • In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $20.9 billion, earnings will come to $3.3 billion, and it would be trading on a PE ratio of 33.1x, assuming you use a discount rate of 7.5%.
  • Given the current share price of $283.7, the analyst price target of $323.71 is 12.4% higher.
  • We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Ecolab?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives

Fair Value vs Share Price

US$323.71
vs US$283.712.4% undervalued intrinsic discount
PastFuture021b2015201820212024202620272029Revenue US$20.9bEarnings US$3.3b
7.5%
Revenue growth
15.8%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Ecolab

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Average dividend payer with mediocre balance sheet.

Market capUS$79.6b
PB7.9x
Estimated Growth6.9%
Dividend Yield1.0%
Full analysis

CEO & management

Christophe Beck
CEO
5.0yrs
CEO Tenure

Provides water, hygiene, and infection prevention solutions and services in the United States and internationally.